Long-term impact of the decrease of infliximab trough levels on the disease course in Inflammatory Bowel Disease patients under maintenance treatment with infliximab

被引：0
|
作者：
Orfanoudaki, E. [1 ]
Gazouli, M. [2 ]
Foteinogiannopoulou, K. [1 ]
Theodoraki, E. [1 ]
Legaki, E. [2 ]
Koutroubakis, I. [1 ]
机构：
[1] Univ Hosp Heraklion, Gastroenterol, Iraklion, Crete, Greece
[2] Natl & Kapodistrian Univ Athens, Dept Basic Med Sci, Lab Biol, Athens, Greece
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P408
引用
收藏
页码：S375 / S376
页数：2
相关论文
共 50 条
  • [31] Comparison of 4 assay kits for measuring infliximab trough levels and antibodies to infliximab in patients with inflammatory bowel disease
    Perez, I.
    Fernandez, L.
    Sanchez-Ramon, S.
    Alba, C.
    Olivares, D.
    Mendoza, J. L.
    Rey, E.
    Taxonera, C.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S380 - S380
  • [32] Infliximab trough levels after induction therapy are predictive for infliximab efficacy in paediatric patients with inflammatory bowel disease
    van Hoeve, K.
    Hoffman, I.
    Dreesen, E.
    Ferrante, M.
    Gils, A.
    Vermeire, S.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S183 - S183
  • [33] Comparison of Four Assay Kits for Measuring Infliximab Trough Levels and Antibodies to Infliximab in Patients With Inflammatory Bowel Disease
    Enciso, Irene Perez
    Paredes, Lidia Fernandez
    Sanchez-Ramon, Silvia
    Mendoza, Juan L.
    Alba, Cristina
    Olivares, David
    Rey, Enrique
    Taxonera, Carlos
    GASTROENTEROLOGY, 2016, 150 (04) : S415 - S415
  • [34] THE CLINICAL AND FINANCIAL IMPACT OF MEASURING INFLIXIMAB LEVELS AND ANTIBODIES TO INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS
    O'Reilly, S.
    Keegan, D.
    Byrne, K.
    Sheridan, J.
    Mulcahy, H. E.
    Doherty, G. A.
    Cullen, G.
    GUT, 2017, 66 : A2 - A3
  • [35] Success and safety of high infliximab trough levels in inflammatory bowel disease
    Drobne, David
    Kurent, Tina
    Golob, Sasa
    Svegl, Polona
    Rajar, Polona
    Terzic, Sara
    Kozelj, Matic
    Novak, Gregor
    Smrekar, Natasa
    Plut, Samo
    Sever, Nejc
    Strnisa, Luka
    Hanzel, Jurij
    Brecelj, Jernej
    Urlep, Darja
    Osredkar, Josko
    Homan, Matjaz
    Orel, Rok
    Stabuc, Borut
    Ferkolj, Ivan
    Smid, Alojz
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2018, 53 (08) : 940 - 946
  • [36] Smoking is associated with low trough serum infliximab levels and presence of anti-infliximab antibody in maintenance treatment of inflammatory bowel disease (IBD)
    Kong, J. Y.
    Bundell, C. S.
    Pawlik, J.
    Hollingsworth, P. N.
    Forbes, G. M.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 : 59 - 59
  • [37] The Course of Infliximab Discontinuation After Long-Term Maintenance Treatment in Crohn's Disease
    Armuzzi, Alessandro
    Rizzi, Marina
    Monterubbianesi, Rita
    Marzo, Manuela
    Cicala, Michele
    Guidi, Luisa
    Prantera, Cosimo
    Kohn, Anna
    GASTROENTEROLOGY, 2010, 138 (05) : S687 - S687
  • [38] Influence of initial albumin levels on infliximab and adalimumab trough levels in inflammatory bowel disease patients
    Gonzalez-Lopez, J.
    Llamas, C.
    Giraldez-Montero, J. M.
    Ferreiro, R.
    Baston, I.
    Lamas, M. J.
    Dominguez-Munoz, J. E.
    Barreiro-de Acosta, M.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S248 - S249
  • [39] Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment
    Krajcovicova, A.
    Batovsky, M.
    Gregus, M.
    Hlista, M.
    Durina, J.
    Leskova, Z.
    Sturdik, I
    Gojdic, M.
    Jalali, Y.
    Koller, T.
    Toth, J.
    Huorka, M.
    Hlavaty, T.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2018, 81 (04) : 465 - 470
  • [40] Long-Term Safety and Efficacy of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease
    Mock, Joseph D.
    Tuskey, Anne G.
    Rubin, Amy
    Behm, Brian W.
    GASTROENTEROLOGY, 2015, 148 (04) : S257 - S257
12345